Latest / Applied Clinical Trials
ACT Brief: AI, Caplyta Approval, and FDA Priority Vouchers
In today’s ACT Brief, we explore how AI and tokenized data are improving patient-protocol matching, highlight Caplyta’s new FDA approval for major depressive disorder, and review the FDA’s expansion of its National Priority Voucher program.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.